Skip to main content

Advertisement

SpringerLink
Log in

Treatment regimens of classical and newer taxanes

  • Review Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

The classical taxanes (paclitaxel, docetaxel), the newer taxane cabazitaxel and the nanoparticle-bound nab-paclitaxel are among the most widely used anticancer drugs. The taxanes share the characteristics of extensive hepatic metabolism and biliary excretion, the need for dose adaptation in patients with liver dysfunction, and a substantial pharmacokinetic variability even after taking into account known covariates. Data from clinical studies suggest that optimal scheduling of the taxanes is dependent not only on the specific taxane compound, but also on the tumor type and line of treatment. Still, the optimal dosing regimen (weekly vs 3 weekly) and optimal dose of the taxanes are controversial, as is the value of pharmacological personalization of taxane dosing. In this article, an overview is given on the pharmacological properties of the taxanes, including metabolism, pharmacokinetics–pharmacodynamics and aspects in the clinical use of taxanes. The latter includes the ongoing debate on the most active and safe regimen, the recommended initial dose and the issue of therapeutic drug dosing.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT (1971) Plant antitumor agents VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93(9):2325–2327

    Article  CAS  PubMed  Google Scholar 

  2. Lavelle F, Gueritte-Voegelein F, Guenard D (1993) Taxotere: from yew’s needles to clinical practice. Bull Cancer 80(4):326–338

    CAS  PubMed  Google Scholar 

  3. Mita AC, Denis LJ, Rowinsky EK, Debono JS, Goetz AD, Ochoa L, Forouzesh B, Beeram M, Patnaik A, Molpus K, Semiond D, Besenval M, Tolcher AW (2009) Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 15(2):723–730

    Article  CAS  PubMed  Google Scholar 

  4. Cisternino S, Bourasset F, Archimbaud Y, Semiond D, Sanderink G, Scherrmann JM (2003) Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats. Br J Pharmacol 138(7):1367–1375

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Jibodh RA, Lagas JS, Nuijen B, Beijnen JH, Schellens JH (2013) Taxanes: old drugs, new oral formulations. Eur J Pharmacol 717(1–3):40–46. doi:10.1016/j.ejphar.2013.02.058

    Article  CAS  PubMed  Google Scholar 

  6. Belani CP, Lee JS, Socinski MA, Robert F, Waterhouse D, Rowland K, Ansari R, Lilenbaum R, Natale RB (2005) Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. Ann Oncol 16(7):1069–1107

    Article  CAS  PubMed  Google Scholar 

  7. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358(16):1663–1671

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, Wood WC (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21(4):588–592

    Article  PubMed  Google Scholar 

  9. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, Bauknecht T, Richter B, Warm M, Schroder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J, Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study G (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95(17):1320–1329

    Article  PubMed  Google Scholar 

  10. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Trope C, Icon, Collaborators AGO (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361(9375):2099–2106

    Article  CAS  PubMed  Google Scholar 

  11. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, Harris JW (1994) Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 54(21):5543–5546

    CAS  PubMed  Google Scholar 

  12. Vaclavikova R, Soucek P, Svobodova L, Anzenbacher P, Simek P, Guengerich FP, Gut I (2004) Different in vitro metabolism of paclitaxel and docetaxel in humans, rats, pigs, and minipigs. Drug Metab Dispos 32(6):666–674

    Article  CAS  PubMed  Google Scholar 

  13. Monsarrat B, Chatelut E, Royer I, Alvinerie P, Dubois J, Dezeuse A, Roche H, Cros S, Wright M, Canal P (1998) Modification of paclitaxel metabolism in a cancer patient by induction of cytochrome P450 3A4. Drug Metab Dispos 26(3):229–233

    CAS  PubMed  Google Scholar 

  14. Burkhart CA, Kavallaris M, Band Horwitz S (2001) The role of beta-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta 1471(2):O1–O9

    CAS  PubMed  Google Scholar 

  15. Andre F, Hatzis C, Anderson K, Sotiriou C, Mazouni C, Mejia J, Wang B, Hortobagyi GN, Symmans WF, Pusztai L (2007) Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin Cancer Res 13(7):2061–2067

    Article  CAS  PubMed  Google Scholar 

  16. Tanaka S, Nohara T, Iwamoto M, Sumiyoshi K, Kimura K, Takahashi Y, Tanigawa N (2009) Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer. Cancer Chemother Pharmacol 64(2):341–346

    Article  CAS  PubMed  Google Scholar 

  17. Tamura T, Sasaki Y, Eguchi K, Shinkai T, Ohe Y, Nishio M, Kunikane H, Arioka H, Karato A, Omatsu H et al (1994) Phase I and pharmacokinetic study of paclitaxel by 24-hour intravenous infusion. Jpn J Cancer Res 85(10):1057–1062

    Article  CAS  PubMed  Google Scholar 

  18. Sonnichsen DS, Hurwitz CA, Pratt CB, Shuster JJ, Relling MV (1994) Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol 12(3):532–538

    CAS  PubMed  Google Scholar 

  19. Karlsson MO, Molnar V, Freijs A, Nygren P, Bergh J, Larsson R (1999) Pharmacokinetic models for the saturable distribution of paclitaxel. Drug Metab Dispos 27(10):1220–1223

    CAS  PubMed  Google Scholar 

  20. van Tellingen O, Huizing MT, Panday VR, Schellens JH, Nooijen WJ, Beijnen JH (1999) Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer 81(2):330–335

    Article  PubMed Central  PubMed  Google Scholar 

  21. Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Lacatelli A, Bonadonna G, Egorin MJ (1995) Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13(1):180–190

    CAS  PubMed  Google Scholar 

  22. Sykes E, Woodburn K, Decker D, Kessel D (1994) Effects of Cremophor EL on distribution of Taxol to serum lipoproteins. Br J Cancer 70(3):401–404

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, Pillay M, Nooter K, Stoter G, Verweij J (1999) Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 59(7):1454–1457

    CAS  PubMed  Google Scholar 

  24. Kumar GN, Walle UK, Bhalla KN, Walle T (1993) Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein. Res Commun Chem Pathol Pharmacol 80(3):337–344

    CAS  PubMed  Google Scholar 

  25. Huizing MT, Vermorken JB, Rosing H, ten Bokkel Huinink WW, Mandjes I, Pinedo HM, Beijnen JH (1995) Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial. Ann Oncol 6(7):699–704

    CAS  PubMed  Google Scholar 

  26. Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E (1987) Phase I clinical and pharmacokinetic study of taxol. Cancer Res 47(9):2486–2493

    CAS  PubMed  Google Scholar 

  27. Joerger M, Kraff S, Huitema AD, Feiss G, Moritz B, Schellens JH, Beijnen JH, Jaehde U (2012) Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study. Clin Pharmacokinet 51(9):607–617

    Article  CAS  PubMed  Google Scholar 

  28. Joerger M, Huitema AD, Huizing MT, Willemse PH, de Graeff A, Rosing H, Schellens JH, Beijnen JH, Vermorken JB (2007) Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic–pharmacodynamic study. Br J Clin Pharmacol 64(5):622–633

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Venook AP, Egorin MJ, Rosner GL, Brown TD, Jahan TM, Batist G, Hohl R, Budman D, Ratain MJ, Kearns CM, Schilsky RL (1998) Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol 16(5):1811–1819

    CAS  PubMed  Google Scholar 

  30. Joerger M, Beumer JH (2013) Cancer treatment in patients with hepatic dysfunction. In: ESMO handbook: Cancer treatments in special clinical situations. ESMO Press, pp 23–30

  31. Joerger M, Huitema AD, van den Bongard DH, Schellens JH, Beijnen JH (2006) Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors. Clin Cancer Res 12(7 Pt 1):2150–2157

    Article  CAS  PubMed  Google Scholar 

  32. Miller AA, Rosner GL, Egorin MJ, Hollis D, Lichtman SM, Ratain MJ (2004) Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763. Clin Cancer Res 10(24):8325–8331

    Article  CAS  PubMed  Google Scholar 

  33. Mould DR, Fleming GF, Darcy KM, Spriggs D (2006) Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group study. Br J Clin Pharmacol 62(1):56–70

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  34. Mielke S, Sparreboom A, Steinberg SM, Gelderblom H, Unger C, Behringer D, Mross K (2005) Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res 11(13):4843–4850

    Article  CAS  PubMed  Google Scholar 

  35. Huizing MT, Giaccone G, van Warmerdam LJ, Rosing H, Bakker PJ, Vermorken JB, Postmus PE, van Zandwijk N, Koolen MG, ten BokkelHuinink WW, van der Vijgh WJ, Bierhorst FJ, Lai A, Dalesio O, Pinedo HM, Veenhof CH, Beijnen JH (1997) Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. J Clin Oncol 15(1):317–329

    CAS  PubMed  Google Scholar 

  36. Joerger M, Huitema AD, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Calvert H, Boddy AV, Hollema H, Fety R, Van der Vijgh WJ, Hempel G, Chatelut E, Karlsson M, Wilkins J, Tranchand B, Schrijvers AH, Twelves C, Beijnen JH, Schellens JH (2007) Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. Clin Cancer Res 13(21):6410–6418

    Article  CAS  PubMed  Google Scholar 

  37. Choy H, Akerley W, Safran H, Clark J, Rege V, Papa A, Glantz M, Puthawala Y, Soderberg C, Leone L (1994) Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. J Clin Oncol 12(12):2682–2686

    CAS  PubMed  Google Scholar 

  38. Huang TC, Campbell TC (2012) Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumors: a meta-analysis. Cancer Treat Rev 38(6):613–617

    Article  CAS  PubMed  Google Scholar 

  39. Schuette W, Blankenburg T, Guschall W, Dittrich I, Schroeder M, Schweisfurth H, Chemaissani A, Schumann C, Dickgreber N, Appel T, Ukena D (2006) Multicenter randomized trial for stage IIIB/IV non-small-cell lung cancer using every-3-week versus weekly paclitaxel/carboplatin. Clin Lung Cancer 7(5):338–343

    Article  CAS  PubMed  Google Scholar 

  40. Belani CP, Ramalingam S, Perry MC, LaRocca RV, Rinaldi D, Gable PS, Tester WJ (2008) Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J Clin Oncol 26(3):468–473

    Article  CAS  PubMed  Google Scholar 

  41. Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26(10):1642–1649

    Article  CAS  PubMed  Google Scholar 

  42. Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E, Aoki D, Jobo T, Kodama S, Terauchi F, Sugiyama T, Ochiai K, Japanese Gynecologic Oncology G (2013) Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol 14(10):1020–1026

    Article  CAS  PubMed  Google Scholar 

  43. Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K, Noda K, Japanese Gynecologic Oncology G (2009) Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 374(9698):1331–1338

    Article  CAS  PubMed  Google Scholar 

  44. Chan J, Brady M, Penson R, Monk B, Boente M, Walker J, Davidson S, DiSilvestro P, O’Malley D, Morgan M, Pearl M, DeGeest K, Michael H (2013) Phase III trial of every-3-weeks paclitaxel vs. dose-dense weekly paclitaxel with carboplatin ± bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT01167712). Int J Gynecol Cancer 23(8):1

    Google Scholar 

  45. Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, Bologna A, Weber B, Raspagliesi F, Panici PB, Cormio G, Sorio R, Cavazzini MG, Ferrandina G, Breda E, Murgia V, Sacco C, Cinieri S, Salutari V, Ricci C, Pisano C, Greggi S, Lauria R, Lorusso D, Marchetti C, Selvaggi L, Signoriello S, Piccirillo MC, Di Maio M, Perrone F, on behalf of the Multicentre Italian Trials in Ovarian c, Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens et du s, Mario Negri Gynecologic O, European Network of Gynaecological Oncological Trial G, Gynecologic Cancer InterGroup I (2014) Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 15(4):396–405

    Article  CAS  PubMed  Google Scholar 

  46. de Jonge ME, van den Bongard HJ, Huitema AD, Mathot RA, Rosing H, Baas P, van Zandwijk N, Beijnen JH, Schellens JH (2004) Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer. Clin Cancer Res 10(7):2237–2244

    Article  PubMed  Google Scholar 

  47. Woo MH, Relling MV, Sonnichsen DS, Rivera GK, Pratt CB, Pui CH, Evans WE, Pappo AS (1999) Phase I targeted systemic exposure study of paclitaxel in children with refractory acute leukemias. Clin Cancer Res 5(3):543–549

    CAS  PubMed  Google Scholar 

  48. Joerger M, von Pawel J, Kraff S, Fischer JR, Eberhardt W, Gauler TC, Mueller L, Reinmuth N, Reck M, Kimmich M, Mayer F, Kopp HG, Behringer DM, Ko YD, Früh M, Hilger RA, Roessler M, Moritz B, Jaehde U (2015) Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin in advanced Non-Small Cell Lung Cancer (NSCLC) patient. In: 2015 ASCO Annual Meeting (May 29–June 2, 2015), Abstract 146973

  49. Joerger M, von Pawel J, Kraff S, Fischer JR, Eberhardt W, Gauler TC, Mueller L, Reinmuth N, Reck M, Kimmich M, Mayer F, Kopp HG, Behringer DM, Ko YD, Hilger RA, Roessler M, Kloft C, Henrich A, Moritz B, Jaehde U (2015) Pharmacokinetically (PK)-guided dosing of paclitaxel in combination with carboplatin in advanced non-small cell lung cancer (NSCLC) is gender dependent: Updated results of the randomized CEPAC-TDM study. European Cancer Congess 2015, Vienna (Austria), Sep 25–29, abstract 3066

  50. Roche H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D, Symann M, Kerbrat P, Soulie P, Eichler F, Viens P, Monnier A, Vindevoghel A, Campone M, Goudier MJ, Bonneterre J, Ferrero JM, Martin AL, Geneve J, Asselain B (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 24(36):5664–5671

    Article  CAS  PubMed  Google Scholar 

  51. Rivera E, Mejia JA, Arun BK, Adinin RB, Walters RS, Brewster A, Broglio KR, Yin G, Esmaeli B, Hortobagyi GN, Valero V (2008) Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer 112(7):1455–1461

    Article  CAS  PubMed  Google Scholar 

  52. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O’Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18(10):2095–2103

    CAS  PubMed  Google Scholar 

  53. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, Investigators TAX (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502–1512

    Article  CAS  PubMed  Google Scholar 

  54. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA, Group VS (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24(31):4991–4997

    Article  PubMed  Google Scholar 

  55. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM Jr, Haddad RI, Group TAXS (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357(17):1705–1715

    Article  CAS  PubMed  Google Scholar 

  56. Qi WX, Shen Z, Lin F, Sun YJ, Min DL, Tang LN, He AN, Yao Y (2013) Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. Curr Med Res Opin 29(2):117–125

    Article  CAS  PubMed  Google Scholar 

  57. Vaishampayan U, Parchment RE, Jasti BR, Hussain M (1999) Taxanes: an overview of the pharmacokinetics and pharmacodynamics. Urology 54(6A Suppl):22–29

    Article  CAS  PubMed  Google Scholar 

  58. Wang H, Vo T, Hajar A, Li S, Chen X, Parissenti AM, Brindley DN, Wang Z (2014) Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells. BMC Cancer 14:37. doi:10.1186/1471-2407-14-37

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  59. Antonarakis ES, Armstrong AJ (2011) Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 14(3):192–205

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  60. van Zuylen L, Sparreboom A, van der Gaast A, Nooter K, Eskens FA, Brouwer E, Bol CJ, de Vries R, Palmer PA, Verweij J (2002) Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933. Eur J Cancer 38(8):1090–1099

    Article  PubMed  Google Scholar 

  61. Fracasso PM, Goldstein LJ, de Alwis DP, Rader JS, Arquette MA, Goodner SA, Wright LP, Fears CL, Gazak RJ, Andre VA, Burgess MF, Slapak CA, Schellens JH (2004) Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. Clin Cancer Res 10(21):7220–7228

    Article  CAS  PubMed  Google Scholar 

  62. Martinez VG, O’Connor R, Liang Y, Clynes M (2008) CYP1B1 expression is induced by docetaxel: effect on cell viability and drug resistance. Br J Cancer 98(3):564–570

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  63. Pastina I, Giovannetti E, Chioni A, Sissung TM, Crea F, Orlandini C, Price DK, Cianci C, Figg WD, Ricci S, Danesi R (2010) Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients. BMC Cancer 10:511

    Article  PubMed Central  PubMed  Google Scholar 

  64. Clarke SJ, Rivory LP (1999) Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 36(2):99–114

    Article  CAS  PubMed  Google Scholar 

  65. Loos WJ, Baker SD, Verweij J, Boonstra JG, Sparreboom A (2003) Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins. Clin Pharmacol Ther 74(4):364–371

    Article  CAS  PubMed  Google Scholar 

  66. Bruno R, Olivares R, Berille J, Chaikin P, Vivier N, Hammershaimb L, Rhodes GR, Rigas JR (2003) Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel. Clin Cancer Res 9(3):1077–1082

    CAS  PubMed  Google Scholar 

  67. Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB (1998) Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16(1):187–196

    CAS  PubMed  Google Scholar 

  68. Tabernero J, Climent MA, Lluch A, Albanell J, Vermorken JB, Barnadas A, Anton A, Laurent C, Mayordomo JI, Estaun N, Losa I, Guillem V, Garcia-Conde J, Tisaire JL, Baselga J (2004) A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 15(9):1358–1365

    Article  CAS  PubMed  Google Scholar 

  69. Schuette W, Nagel S, Blankenburg T, Lautenschlaeger C, Hans K, Schmidt EW, Dittrich I, Schweisfurth H, von Weikersthal LF, Raghavachar A, Reissig A, Serke M (2005) Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 23(33):8389–8395

    Article  CAS  PubMed  Google Scholar 

  70. Baker SD, Zhao M, Lee CK, Verweij J, Zabelina Y, Brahmer JR, Wolff AC, Sparreboom A, Carducci MA (2004) Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Clin Cancer Res 10(6):1976–1983

    Article  CAS  PubMed  Google Scholar 

  71. Engels FK, Loos WJ, van der Bol JM, de Bruijn P, Mathijssen RH, Verweij J, Mathot RA (2011) Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic study. Clin Cancer Res 17(2):353–362

    Article  CAS  PubMed  Google Scholar 

  72. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO, Investigators T (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747):1147–1154

    Article  PubMed  Google Scholar 

  73. Girard E, Ditzler S, Lee D, Richards A, Yagle K, Park J, Eslamy H, Bobilev D, Vrignaud P, Olson J (2014) Efficacy of cabazitaxel in mouse models of pediatric brain tumors. Neuro Oncol 17(1):107–115

    Article  PubMed Central  PubMed  Google Scholar 

  74. Pean E, Demolis P, Moreau A, Hemmings RJ, O’Connor D, Brown D, Shepard T, Abadie E, Pignatti F (2012) The European Medicines Agency review of cabazitaxel (Jevtana(R)) for the treatment of hormone-refractory metastatic prostate cancer: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist 17(4):543–549

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  75. Vrignaud P, Semiond D, Lejeune P, Bouchard H, Calvet L, Combeau C, Riou JF, Commercon A, Lavelle F, Bissery MC (2013) Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors. Clin Cancer Res 19(11):2973–2983

    Article  CAS  PubMed  Google Scholar 

  76. Ferron GM, Dai Y, Semiond D (2013) Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 71(3):681–692

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  77. Dieras V, Lortholary A, Laurence V, Delva R, Girre V, Livartowski A, Assadourian S, Semiond D, Pierga JY (2013) Cabazitaxel in patients with advanced solid tumours: results of a Phase I and pharmacokinetic study. Eur J Cancer 49(1):25–34

    Article  CAS  PubMed  Google Scholar 

  78. Fumoleau P, Trigo JM, Isambert N, Semiond D, Gupta S, Campone M (2013) Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours. BMC Cancer 13:460

    Article  PubMed Central  PubMed  Google Scholar 

  79. Heidenreich A, Scholz HJ, Rogenhofer S, Arsov C, Retz M, Muller SC, Albers P, Gschwend J, Wirth M, Steiner U, Miller K, Heinrich E, Trojan L, Volkmer B, Honecker F, Bokemeyer C, Keck B, Otremba B, Ecstein-Fraisse E, Pfister D (2013) Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme. Eur Urol 63(6):977–982

    Article  CAS  PubMed  Google Scholar 

  80. Paal K, Muller J, Hegedus L (2001) High affinity binding of paclitaxel to human serum albumin. Eur J Biochem 268(7):2187–2191

    Article  CAS  PubMed  Google Scholar 

  81. Watkins G, Douglas-Jones A, Bryce R, Mansel RE, Jiang WG (2005) Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukot Essent Fatty Acids 72(4):267–272

    Article  CAS  PubMed  Google Scholar 

  82. Sinn M, Sinn BV, Striefler JK, Lindner JL, Stieler JM, Lohneis P, Bischoff S, Blaker H, Pelzer U, Bahra M, Dietel M, Dorken B, Oettle H, Riess H, Denkert C (2014) SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study. Ann Oncol 25(5):1025–1032

    Article  CAS  PubMed  Google Scholar 

  83. Bookman MA, Kloth DD, Kover PE, Smolinski S, Ozols RF (1997) Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Ann Oncol 8(6):611–614

    Article  CAS  PubMed  Google Scholar 

  84. Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, Esmaeli B, Ring SE, Bedikian A, Hortobagyi GN, Ellerhorst JA (2002) Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8(5):1038–1044

    CAS  PubMed  Google Scholar 

  85. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691–1703

    Article  Google Scholar 

  86. Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A, Bhar P (2009) Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 27(22):3611–3619

    Article  CAS  PubMed  Google Scholar 

  87. Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P, Zhang H, Iglesias JL, Renschler MF (2012) Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 30(17):2055–2062

    Article  CAS  PubMed  Google Scholar 

  88. Schubert W, Frank PG, Razani B, Park DS, Chow CW, Lisanti MP (2001) Caveolae-deficient endothelial cells show defects in the uptake and transport of albumin in vivo. J Biol Chem 276(52):48619–48622

    Article  CAS  PubMed  Google Scholar 

  89. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O’Shaughnessy J (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23(31):7794–7803

    Article  CAS  PubMed  Google Scholar 

  90. Chen N, Li Y, Ye A, Palmisano M, Chopra R, Zhou S (2014) Population pharmacokinetics (PK) and exposure–neutropenia relationship of nab-paclitaxel (nab-P) in patients with solid tumors. J Clin Oncol 32:5s

  91. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, Tao C, De T, Beals B, Dykes D, Noker P, Yao R, Labao E, Hawkins M, Soon-Shiong P (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12(4):1317–1324

    Article  CAS  PubMed  Google Scholar 

  92. Biakhov MY, Kononova GV, Iglesias J, Desai N, Bhar P, Schmid AN, Loibl S (2010) nab-Paclitaxel in patients with advanced solid tumors and hepatic dysfunction: a pilot study. Expert Opin Drug Saf 9(4):515–523

    Article  CAS  PubMed  Google Scholar 

  93. Socinski MA, Manikhas GM, Stroyakovsky DL, Makhson AN, Cheporov SV, Orlov SV, Yablonsky PK, Bhar P, Iglesias J (2010) A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 5(6):852–861

    Article  PubMed  Google Scholar 

  94. Saito K, Kikuchi Y, Fujii K, Kita T, Furuya K (2006) Effect of paclitaxel on vascular endothelial growth factor (VEGF) and interleukin (IL)-8 in serum of patients with recurrent ovarian cancer: a comparison of weekly vs triweekly regimens. Target Oncol 1:86–89

    Article  Google Scholar 

  95. Beumer JH (2013) Without therapeutic drug monitoring, there is no personalized cancer care. Clin Pharmacol Ther 93(3):228–230

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology and Hematology, Cantonal Hospital, Rorschacherstrasse 95, St. Gallen, 9007, Switzerland

    Markus Joerger

Authors
  1. Markus Joerger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Markus Joerger.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Joerger, M. Treatment regimens of classical and newer taxanes. Cancer Chemother Pharmacol 77, 221–233 (2016). https://doi.org/10.1007/s00280-015-2893-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-015-2893-6

Keywords

Search

Navigation